Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00352794 · ClinicalTrials.gov registry record · Phase 2

Lenalidomide for Patients With Myelofibrosis (MF)

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target

NCT00352794: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT00352794 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00352794, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

The goal of this clinical research study is to learn if lenalidomide in combination with prednisone can help to control myelofibrosis. The safety of lenalidomide and prednisone for the treatment of myelofibrosis will also be studied.

Primary Outcome

Time to response defined as the time from start of therapy until the response criteria are fulfilled. Response duration defined as the time from response until relapse (progressive disease) or death.

Interventions

  • DRUG Lenalidomide
  • DRUG Prednisone

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2006-07-07
Est. Completion 2018-03-08
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00352794 record still lists

NCT00352794 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.

NCT00352794 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00352794 about?

NCT00352794 is a clinical study titled "Lenalidomide for Patients With Myelofibrosis (MF)". The goal of this clinical research study is to learn if lenalidomide in combination with prednisone can help to control myelofibrosis. The safety of lenalidomide and prednisone for the treatment of myelofibrosis will also be studied.

What is the current status of trial NCT00352794?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2006-07-07. Estimated completion is 2018-03-08.

What interventions are being tested in trial NCT00352794?

The interventions under investigation include: Lenalidomide (DRUG), Prednisone (DRUG).

Who is sponsoring clinical trial NCT00352794?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00352794's enrollment target sits among peer trials

40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00352794, the US trial registry maintained by the National Library of Medicine. NCT00352794 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.